Cboe UK SEK

Episurf Medical AB (publ) (EPISBS.XC)

Compare
0.2365
0.0000
(0.00%)
At close: July 3 at 11:43:47 AM GMT+1
Loading Chart for EPISBS.XC
DELL
  • Previous Close 0.2365
  • Open 0.2360
  • Bid --
  • Ask --
  • Day's Range 0.2365 - 0.2365
  • 52 Week Range 0.2360 - 3.0100
  • Volume 12
  • Avg. Volume 0
  • Market Cap (intraday) 153.962M
  • Beta (5Y Monthly) 0.99
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2400
  • Earnings Date Feb 6, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also provides Episealer Talus, a solution for the treatment of bone and cartilage defects in the talus bone of the ankle joint; Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient's distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.

episurf.com

26

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EPISBS.XC

View More

Performance Overview: EPISBS.XC

Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

EPISBS.XC
0.00%
OMX Stockholm 30 Index
5.41%

1-Year Return

EPISBS.XC
92.14%
OMX Stockholm 30 Index
12.64%

3-Year Return

EPISBS.XC
92.14%
OMX Stockholm 30 Index
10.99%

5-Year Return

EPISBS.XC
87.93%
OMX Stockholm 30 Index
44.42%

Compare To: EPISBS.XC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EPISBS.XC

View More

Valuation Measures

Annual
As of 1/17/2025
  • Market Cap

    85.86M

  • Enterprise Value

    22.16M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.20

  • Price/Book (mrq)

    1.31

  • Enterprise Value/Revenue

    1.24

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.60%

  • Return on Equity (ttm)

    -76.77%

  • Revenue (ttm)

    12.5M

  • Net Income Avi to Common (ttm)

    -79.8M

  • Diluted EPS (ttm)

    -0.2400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    66.8M

  • Total Debt/Equity (mrq)

    3.05%

  • Levered Free Cash Flow (ttm)

    -57.09M

Research Analysis: EPISBS.XC

View More

Company Insights: EPISBS.XC

Research Reports: EPISBS.XC

View More